Epoetin alfa and darbepoetin alfa go head to head

Journal of Clinical Oncology

Volumn 24, Issue 15, 2006, Pages 2232-2236

  Steensma, David P ^a   Loprinzi, Charles L ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

AMINO ACID SEQUENCE; ANEMIA; BIOEQUIVALENCE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG BINDING; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG STRUCTURE; EDITORIAL; ERYTHROCYTE TRANSFUSION; FOOD AND DRUG ADMINISTRATION; HUMAN; LOADING DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNITED STATES; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; NEOPLASM; NOTE; PHARMACOKINETICS;

ANEMIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; ERYTHROPOIETIN; HEMATINICS; HUMANS; NEOPLASMS; THERAPEUTIC EQUIVALENCY;

EID: 33744832189     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.7794     Document Type: Editorial

References (31)

1. Spivak JL: The anaemia of cancer: Death by a thousand cuts. Nat Rev Cancer 5:543-555, 2005
2. Egrie JC, Browne JK: Development and characterization of darbepoetin alfa. Oncology (Williston Park) 16:13-22, 2002
3. Amgen: Amgen Fact Sheets: Hematology. Thousand Oaks, CA, Amgen, 2006
4. Mirtsching B, Charu V, Vadhan-Raj S, et al: Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia: Results of a combined analysis. Oncology (Williston Park) 16:31-36, 2002
5. Vadhan-Raj S, Mirtsching B, Charu V, et al: Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 1:131-138, 2003
6. Schwartzberg L, Shiffman R, Tomita D, et al: A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther 25:2781-2796, 2003
7. Glaspy JA, Jadeja JS, Justice G, et al: Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 87:268-276, 2002
8. Glaspy J, Vadhan-Raj S, Patel R, et al: Randomized comparison of every-2-weeks darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 20030125 Study Group trial. J Clin Oncol 24:2290-2297, 2006
9. Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group. J Clin Oncol 15:1218-1234, 1997
10. Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459-460, 2003
11. Henke M, Laszig R, Rube C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260, 2003
12. Steensma DP: Management of anemia in patients with cancer. Curr Oncol Rep 6:297-304, 2004
13. Campos SM, Duh MS, Lefebvre P, et al: Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Canc Netw 3:807-816, 2005
14. Witzig TE, Silberstein PT, Loprinzi CL, et al: Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606-2617, 2005
15. Seidenfeld J, Piper M, Flamm C, et al: Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93:1204-1214, 2001
16. Waltzman R, Croot C, Justice GR, et al: Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 10:642-650, 2005
17. Case AS, Rocconi RP, Kilgore LC, et al: Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies. Gynecol Oncol doi:10.1016/j.ygyno .2005.11.027
18. Schwartzberg LS, Yee LK, Senecal FM, et al: A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 9:696-707, 2004
19. Senecal FM, Yee L, Gabrail N, et al: Treatment of chemotherapy-induced anemia in breast cancer: Results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer 6:446-454, 2005
20. Steensma DP, Molina R, Sloan JA, et al: Phase III randomized trial of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 24:1079-1089, 2006
21. Glaspy JA, Jadeja JS, Justice G, et al: A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 97: 1312-1320, 2003
22. Canon JL, Vansteenkiste J, Bodoky G, et al: Results of a randomised, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks for the treatment of anaemia in patients receiving multicycle chemotherapy. Proceedings of the 10th Congress of the European Hematology Association, Stockholm, Sweden, June 2-5, 2005 (abstr 0471)
23. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882, 2001
24. Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107, 2002
25. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee: Minutes of the meeting of Tuesday, May 4, 2004. Gaithersburg, MD, 2004
26. Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100:2303-2320, 2002
27. Auerbach M, Ballard H, Trout JR, et al: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 22:1301-1307, 2004
28. Steensma DP, Witzig TE: Does treatment with recombinant human erythropoietin affect the survival of anemic patients with cancer? Nat Clin Pract Oncol 2:444-445, 2005
29. Maiese K, Li F, Chong ZZ: New avenues of exploration for erythropoietin. JAMA 293:90-95, 2005
30. Macdougall IC: CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 4:436-440, 2005
31. Tillmann HC, Kuhn B, Kranzlin B, et al: Efficacy and immunogenicity of novel erythropoietic agents and conventional rhEPO in rats with renal insufficiency. Kidney Int 69:60-67, 2006